Business Description
Founded in 2012 and based in San Diego, California, Connect Biopharma Holdings Limited is working to bring new treatments to patients suffering from conditions where the immune system causes harmful inflammation. Its most advanced drug, rademikibart, blocks a specific protein receptor involved in triggering such reactions and is currently being tested in large-scale clinical trials for atopic dermatitis and asthma.
